drugset / Trial / NCT06613763

A Study of RAY1225 in Participants With Impaired Kidney Function

NCT06613763

Phase 1 Completed 32 enrolled Guangdong Raynovent Biotech Co., Ltd
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Timeline

Start
2024-09-11
Primary completion
2025-01-10
Completion
2025-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject RAY1225 Unknown 3 mg Subcutaneous